Compare SMID & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | TLSI |
|---|---|---|
| Founded | 1960 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.7M | 244.3M |
| IPO Year | 1995 | N/A |
| Metric | SMID | TLSI |
|---|---|---|
| Price | $36.00 | $7.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 8.7K | ★ 258.1K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.92 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $88,866,000.00 | $40,207,000.00 |
| Revenue This Year | N/A | $55.06 |
| Revenue Next Year | N/A | $46.04 |
| P/E Ratio | $15.89 | ★ N/A |
| Revenue Growth | 16.37 | ★ 49.52 |
| 52 Week Low | $25.13 | $3.42 |
| 52 Week High | $48.41 | $7.70 |
| Indicator | SMID | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 69.62 |
| Support Level | $33.33 | $6.96 |
| Resistance Level | $36.68 | $7.53 |
| Average True Range (ATR) | 1.67 | 0.51 |
| MACD | 0.41 | -0.00 |
| Stochastic Oscillator | 82.00 | 84.86 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.